Serum amyloid A: High-density lipoproteins interaction and cardiovascular risk

European Heart Journal

Volumn 36, Issue 43, 2015, Pages 3007-3016

  Zewinger, Stephen ^a   Drechsler, Christiane ^b   Kleber, Marcus E ^c   Dressel, Alexander ^c   Riffel, Julia ^a   Triem, Sarah ^a   Lehmann, Marlene ^a   Kopecky, Chantal ^d   Saemann, Marcus D ^d   Lepper, Philipp M ^a   Silbernagel, Gunther ^e   Scharnagl, Hubert ^f   Ritsch, Andreas ^g   Thorand, Barbara ^h   De Las Heras Gala, Tonia ^h   Wagenpfeil, Stefan ^a   Koenig, Wolfgang ^i,j,k   Peters, Annette ^h   Laufs, Ulrich ^a   Wanner, Christoph ^b   Fliser, Danilo ^a   Speer, Thimoteus ^a   Marz, Winfried ^c,f,l   more..

^a SAARLAND UNIVERSITY   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e BERN UNIVERSITY HOSPITAL   (Switzerland)

^f MEDICAL UNIVERSITY OF GRAZ   (Austria)

^g INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^h INSTITUTE OF EPIDEMIOLOGY   (Germany)

ⁱ UNIVERSITY HOSPITAL ULM   (Germany)

^j TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^k DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^l SYNLAB ACADEMY   (Germany)

more..

Author keywords

High density lipoprotein Serum amyloid A Cardiovascular risk Mortality Dysfunctional HDL

Indexed keywords

HIGH DENSITY LIPOPROTEIN; SERUM AMYLOID A; BIOLOGICAL MARKER; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CALCULATION; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CAUSE OF DEATH; CLINICAL OBSERVATION; FEMALE; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; ACUTE CORONARY SYNDROME; AORTA; BIOSYNTHESIS; BLOOD; CARDIOVASCULAR DISEASE; CELL CULTURE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC NEPHROPATHY; HEMODIALYSIS; METABOLISM; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSIOLOGY; PROGNOSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; VASCULAR ENDOTHELIUM;

ACUTE CORONARY SYNDROME; ADULT; AGED; AORTA; BIOMARKERS; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; CELLS, CULTURED; CHOLESTEROL, HDL; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NITRIC OXIDE; PROGNOSIS; PROSPECTIVE STUDIES; REACTIVE OXYGEN SPECIES; RENAL DIALYSIS; RISK FACTORS; SERUM AMYLOID A PROTEIN; VASCULAR CELL ADHESION MOLECULE-1;

EID: 84983119263     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehv352     Document Type: Article

References (33)

1. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, Dallongeville J, De Backer G, Ebrahim S, Gjelsvik B, Herrmann-Lingen C, Hoes A, Humphries S, Knapton M, Perk J, Priori SG, Pyorala K, Reiner Z, Ruilope L, Sans-Menendez S, Op Reimer WS, Weissberg P, Wood D, Yarnell J, Zamorano JL, Walma E, Fitzgerald T, Cooney MT, Dudina A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Funck-Brentano C, Filippatos G, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Altiner A, Bonora E, Durrington PN, Fagard R, Giampaoli S, Hemingway H, Hakansson J, Kjeldsen SE, Larsen ML, Mancia G, Manolis AJ, Orth-Gomer K, Pedersen T, Rayner M, Ryden L, Sammut M, Schneiderman N, Stalenhoef AF, Tokgozoglu L, Wiklund O, Zampelas A, European Society of Cardiology, European Association for Cardiovascular Prevention and Rehabilitation, Council on Cardiovascular Nursing, European Association for Study of Diabetes, International Diabetes Federation Europe, European Stroke Initiative, Society of Behavioural Medicine, European Society of Hypertension, WONCA Europe, European Heart Network, European Atherosclerosis Society. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007;14(Suppl. 2): S1-S113.
2. Ortiz A, Covic A, Fliser D, Fouque D, Goldsmith D, Kanbay M, Mallamaci F, Massy ZA, Rossignol P, Vanholder R, Wiecek A, Zoccali C, London GM, Board of the E-mWGoERAE. Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure. Lancet 2014;383:1831-1843.
3. Speer T, Owala FO, Holy EW, Zewinger S, Frenzel FL, Stahli BE, Razavi M, Triem S, Cvija H, Rohrer L, Seiler S, Heine GH, Jankowski V, Jankowski J, Camici GG, Akhmedov A, Fliser D, Luscher TF, Tanner FC. Carbamylated low-density lipopro-tein induces endothelial dysfunction. Eur Heart J 2014;35:3021-3032.
4. Mineo C, Shaul PW. Novel biological functions of high-density lipoprotein cholesterol. Circ Res 2012;111:1079-1090.
5. Luscher TF, Landmesser U, von Eckardstein A, Fogelman AM. High-density lipopro-tein: vascular protective effects, dysfunction, and potential as therapeutic target. Circ Res 2014;114:171-182.
6. Spieker LE, Sudano I, Hurlimann D, Lerch PG, Lang MG, Binggeli C, Corti R, Ruschitzka F, Luscher TF, Noll G. High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation 2002;105:1399-1402.
7. Miller NE, Thelle DS, Forde OH, Mjos OD. The Tromso Heart-study. High-density lipoprotein and coronary heart-disease: a prospective case-control study. Lancet 1977;1:965-968.
8. Sorrentino SA, Besler C, Rohrer L, Meyer M, Heinrich K, Bahlmann FH, Mueller M, Horvath T, Doerries C, Heinemann M, Flemmer S, Markowski A, Manes C, Bahr MJ, Haller H, von Eckardstein A, Drexler H, Landmesser U. Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mel-litus but are improved after extended-release niacin therapy. Circulation 2010;121: 110-122.
9. Speer T, Rohrer L, Blyszczuk P, Shroff R, Kuschnerus K, Kränkel N, Kania G, Zewinger S, Akhmedov A, Shi Y, Martin T, Perisa D, Winnik S, Müller MF, Sester U, Wernicke G, Jung A, Gutteck U, Eriksson U, Geisel J, Deanfield J, von Eckardstein A, Lüscher TF, Fliser D, Bahlmann FH, Landmesser U. Abnormal high-density lipoprotein induces endothelial dysfunction via activation of toll-like receptor-2. Immunity 2013;38:754-768.
10. Speer T, Zewinger S, Fliser D. Uraemic dyslipidaemia revisited: role of high-density lipoprotein. Nephrol Dial Transpl 2013;28:2456-2463.
11. Zewinger S, Speer T, Kleber ME, Scharnagl H, Woitas R, Lepper PM, Pfahler K, Seiler S, Heine GH, Marz W, Silbernagel G, Fliser D. HDL cholesterol is not associated with lower mortality in patients with kidney dysfunction. J Am Soc Nephrol 2014;25:1073-1082.
12. Charakida M, Besler C, Batuca JR, Sangle S, Marques S, Sousa M, Wang G, Tousoulis D, Delgado Alves J, Loukogeorgakis SP, Mackworth-Young C, D'Cruz D, Luscher T, Landmesser U, Deanfield JE. Vascular abnormalities, paraox-onase activity, and dysfunctional HDL in primary antiphospholipid syndrome. JAMA 2009;302:1210-1217.
13. Holzer M, Birner-Gruenberger R, Stojakovic T, El-Gamal D, Binder V, Wadsack C, Heinemann A, Marsche G. Uremia alters HDL composition and function. J Am Soc Nephrol 2011;22:1631-1641.
14. Weichhart T, Kopecky C, Kubicek M, Haidinger M, Doller D, Katholnig K, Suarna C, Eller P, Tolle M, Gerner C, Zlabinger GJ, van der Giet M, Horl WH, Stocker R, Saemann MD. Serum amyloid A in uremic HDL promotes inflammation. J Am Soc Nephrol 2012;23:934-947.
15. Kopecky C, Genser B, Drechsler C, Krane V, Kaltenecker CC, Hengstschlager M, Marz W, Wanner C, Saemann MD, Weichhart T. Quantification of HDL proteins, cardiac events, and mortality in patients with type 2 diabetes on hemodialysis. Clin J Am Soc Nephrol 2015;10:224-231.
16. Kopecky C, Haidinger M, Birner-Grunberger R, Darnhofer B, Kaltenecker CC, Marsche G, Holzer M, Weichhart T, Antlanger M, Kovarik JJ, Werzowa J, Hecking M, Saemann MD. Restoration of renal function does not correct impairment of uremic HDL properties. J Am Soc Nephrol 2015;26:565-575.
17. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, Gallimore JR, Pepys MB. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ 2000;321:199-204.
18. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-843.
19. Winkelmann BR, Marz W, Boehm BO, Zotz R, Hager J, Hellstern P, Senges J. Rationale and design of the LURIC study-a resource for functional genomics, pharmacogenomics and long-term prognosis of cardiovascular disease. Pharmaco-genomics 2001;2:S1-S73.
20. Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, Ritz E. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353:238-248.
21. Holle R, Happich M, Lowel H, Wichmann HE; MONICA/KORA Study Group. KORA-a research platform for population based health research. Gesundheitswe-sen 2005;67(Suppl. 1):S19-S25.
22. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999;340: 115-126.
23. Ridker PM, Rifai N, Pfeffer M, Sacks F, Lepage S, Braunwald E. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocar-dial infarction. Circulation 2000;101:2149-2153.
24. Johnson BD, Kip KE, Marroquin OC, Ridker PM, Kelsey SF, Shaw LJ, Pepine CJ, Sharaf B, Bairey Merz CN, Sopko G, Olson MB, Reis SE, National Heart Lung and Blood Institute. Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women: the National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE). Circulation 2004;109:726-732.
25. Morrow DA, Rifai N, Antman EM, Weiner DL, McCabe CH, Cannon CP, Braunwald E. Serum amyloid A predicts early mortality in acute coronary syndromes: a TIMI 11A substudy. J Am Coll Cardiol 2000;35:358-362.
26. Speer T, Rohrer L, Blyszczuk P, Shroff R, Kuschnerus K, Krankel N, Kania G, Zewinger S, Akhmedov A, Shi Y, Martin T, Perisa D, Winnik S, Muller MF, Sester U, Wernicke G, Jung A, Gutteck U, Eriksson U, Geisel J, Deanfield J, von Eckardstein A, Luscher TF, Fliser D, Bahlmann FH, Landmesser U. Abnormal high-density lipoprotein induces endothelial dysfunction via activation of Toll-like receptor-2. Immunity 2013;38:754-768.
27. Silbernagel G, Schottker B, Appelbaum S, Scharnagl H, Kleber ME, Grammer TB, Ritsch A, Mons U, Holleczek B, Goliasch G, Niessner A, Boehm BO, Schnabel RB, Brenner H, Blankenberg S, Landmesser U, Marz W. High-density lipoprotein cholesterol, coronary artery disease, and cardiovascular mortality. Eur Heart J 2013;34:3563-3571.
28. Silbernagel G, Genser B, Drechsler C, Scharnagl H, Grammer TB, Stojakovic T, Krane V, Ritz E, Wanner C, Marz W. HDL cholesterol, apolipoproteins, and cardiovascular risk in hemodialysis patients. J Am Soc Nephrol 2014;26:484-492.
29. Artl A, Marsche G, Lestavel S, Sattler W, Malle E. Role of serum amyloid A during metabolism of acute-phase HDL by macrophages. Arterioscler Thromb Vasc Biol 2000;20:763-772.
30. Lewis KE, Kirk EA, McDonald TO, Wang S, Wight TN, O'Brien KD, Chait A. Increase in serum amyloid a evoked by dietary cholesterol is associated with increased atherosclerosis in mice. Circulation 2004;110:540-545.
31. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B, for the ILLUMINATE Investigators. Effects of torce-trapib in patients at high risk for coronary events. N Engl J Med 2007;357: 2109-2122.
32. Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Mundl H, Nicholls SJ, Shah PK, Tardif JC, Wright RS, for the dal-OUTCOMES Investigators. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012;367:2089-2099.
33. Kinlay S, Schwartz GG, Olsson AG, Rifai N, Leslie SJ, Sasiela WJ, Szarek M, Libby P, Ganz P, Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering Study I. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation 2003; 108:1560-1566.